Stock analysts at Berenberg Bank started coverage on shares of Clinigen Group PLC (LON:CLIN) in a research note issued on Wednesday. The firm set a “hold” rating and a GBX 1,200 ($15.84) price target on the stock. Berenberg Bank’s target price points to a potential upside of 1.95% from the stock’s current price.

Several other brokerages have also recently issued reports on CLIN. Peel Hunt upgraded Clinigen Group PLC to a “buy” rating and upped their target price for the company from GBX 1,200 ($15.84) to GBX 1,350 ($17.81) in a report on Tuesday, October 10th. Numis Securities Ltd cut Clinigen Group PLC to an “add” rating and set a GBX 1,100 ($14.52) target price for the company. in a report on Tuesday, July 18th. Two investment analysts have rated the stock with a hold rating and three have issued a buy rating to the stock. Clinigen Group PLC has an average rating of “Buy” and an average target price of GBX 1,103 ($14.56).

Clinigen Group PLC (LON:CLIN) opened at 1175.00 on Wednesday. The stock’s 50 day moving average price is GBX 1,108.97 and its 200-day moving average price is GBX 978.53. Clinigen Group PLC has a 52-week low of GBX 695.00 and a 52-week high of GBX 1,187.00. The company’s market capitalization is GBX 1.35 billion.

Clinigen Group PLC (LON:CLIN) last issued its earnings results on Thursday, September 28th. The company reported GBX 41.80 ($0.55) earnings per share (EPS) for the quarter, beating the Thomson Reuters’ consensus estimate of GBX 41.20 ($0.54) by GBX 0.60 ($0.01). The company had revenue of £302.30 million during the quarter. Clinigen Group PLC had a return on equity of 0.98% and a net margin of 0.70%.

ILLEGAL ACTIVITY WARNING: This story was originally reported by Watch List News and is owned by of Watch List News. If you are accessing this story on another site, it was illegally stolen and republished in violation of U.S. & international copyright and trademark legislation. The original version of this story can be read at

In other Clinigen Group PLC news, insider John Bacon sold 250,000 shares of the company’s stock in a transaction on Monday, October 2nd. The stock was sold at an average price of GBX 1,093 ($14.42), for a total value of £2,732,500 ($3,605,832.67). Also, insider Shaun Edward Chilton sold 100,000 shares of the company’s stock in a transaction on Friday, October 13th. The shares were sold at an average price of GBX 1,150 ($15.18), for a total value of £1,150,000 ($1,517,550.80).

Clinigen Group PLC Company Profile

Analyst Recommendations for Clinigen Group PLC (LON:CLIN)

Receive News & Ratings for Clinigen Group PLC Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Clinigen Group PLC and related companies with Analyst Ratings Network's FREE daily email newsletter.